GlassScriptPhysician profile
Nicholas A Seman
NPI 1467832527
$2,785.96
in general payments reported to CMS, 2019-2025
33 companies · $293 in 2025
The $293 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $624 · 2020: $60.85 · 2021: $417 · 2022: $271 · 2023: $372 · 2024: $748 · 2025: $293.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,413.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,412.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $670.51 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Supernus Pharmaceuticals, INC. | $250.63 | 2024 | Qelbree |
| Abbvie INC. | $170.03 | 2021-2025 | Vraylar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $155.82 | 2019-2024 | Jardiance |
| Abbott Laboratories | $138.07 | 2022-2025 | Freestyle Libre 3 |
| Lilly USA, LLC | $133.10 | 2019-2025 | Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $120.74 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Insulet Corporation | $98.70 | 2021 | |
| Dexcom, INC. | $92.95 | 2021-2025 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $89.83 | 2019 | |
| Sanofi-Aventis U.S. LLC | $87.51 | 2019-2022 | |
| Shield Therapeutics INC | $76.35 | 2024 | |
| Amgen INC. | $75.13 | 2019-2025 | Repatha, Evenity, Prolia |
| Xeris Pharmaceuticals, INC. | $74.71 | 2022-2024 | Gvoke Hypopen |
| Exact Sciences Corporation | $61.27 | 2023-2025 | Cologuard Collection Kit |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $58.26 | 2020-2023 | Trintellix |
| Axsome Therapeutics, INC. | $47.63 | 2024 | Auvelity |
| Glaxosmithkline, LLC. | $39.30 | 2019-2025 | Shingrix, Arexvy |
| Astellas Pharma US INC | $37.67 | 2024 | Veozah |
| Janssen Pharmaceuticals, INC | $34.47 | 2019 | |
| Novartis Pharmaceuticals Corporation | $32.61 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $31.69 | 2024-2025 | Gardasil 9, M-M-R II, Vaxneuvance |
| Sumitomo Pharma America, INC. | $26.57 | 2025 | Gemtesa |
| Otsuka America Pharmaceutical, INC. | $23.68 | 2022 | |
| Sobi, INC | $21.72 | 2019 | |
| Genentech USA, INC. | $21.27 | 2019 | |
| Dynavax Technologies Corporation | $20.66 | 2023 | Heplisav-B |
| Biohaven Pharmaceuticals, INC. | $19.84 | 2021 | |
| Ironshore Pharmaceuticals INC. | $19.79 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.28 | 2025 | |
| Pfizer INC. | $13.46 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $12.78 | 2019 | |
| Amarin Pharma, INC. | $11.93 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Seman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.